Aligos Therapeutics (ALGS) Preferred Stock Liabilities (2019 - 2020)

Aligos Therapeutics (ALGS) has reported Preferred Stock Liabilities for 2 consecutive years, with $14.6 million the latest figure, recorded in Q3 2020.

• For the quarter ending Q3 2020, Preferred Stock Liabilities fell 85.52% year-over-year to $14.6 million; the trailing twelve-month figure through Sep 2020 stood at $14.6 million (down 85.52% YoY), and the FY2019 full-year result was $3.2 million, changed N/A from the prior year.
• Preferred Stock Liabilities slipped to $14.6 million in Q3 2020 per ALGS's latest filing, from $101.2 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $101.2 million in Q1 2020 and bottomed at $3.2 million in Q4 2019.